Progenity to Participate in Two Upcoming Investor Conferences
February 10, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Reaches Two Million Test Milestone
January 20, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Provides Financial Guidance for Full-year 2021
January 13, 2021 16:05 ET
|
Progenity, Inc.
Total 2021 revenue expected to grow by up to 30%1, reaching a range of $130 to $145 million Core molecular testing2 volume expected to grow by up to 16% SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE)...
Victorian Era History, Mystery and Death Puts Readers at the Edge of Their Seats in New Suspense Novel
January 11, 2021 09:12 ET
|
XlibrisAU
SYDNEY, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Author of the medieval trilogy books, “A Wicked Winter,” “The Secret Face” and “The Chalcedony Axe,” Richard Watkins introduces a new gothic mystery novel...
Progenity to Present at the 2021 ICR Conference
January 05, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Expands Availability of COVID-19 PCR Testing Services Across United States
December 17, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Closing of the Convertible Senior Notes Offering and Partial Exercise of the Initial Purchaser’s Option to Purchase Additional Notes
December 08, 2020 07:31 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Closing of Public Offering of Common Stock
December 08, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
Progenity, Inc. Prices $75.0 Million Convertible Senior Notes Offering
December 02, 2020 23:51 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior notes...
Progenity Announces Pricing of Public Offering of Common Stock
December 02, 2020 23:50 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...